Compare
CytoDyn Inc. vs Actuate Therapeutics, Inc. vs Exicure, Inc. vs Chemomab Therapeutics Ltd.
| Latest fiscal year | CytoDyn Inc. CYDY | Actuate Therapeutics, Inc. ACTU | Exicure, Inc. XCUR | Chemomab Therapeutics Ltd. CMMB |
|---|---|---|---|---|
| Year ended | 2026-05-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$42.70M | -$22.23M | -$4.95M | -$8.99M |
| EPS (Diluted) | -$0.03 | -$1.06 | -$0.79 | $0.018 |
| Operating cash flow | -$17.25M | -$19.21M | -$8.55M | -$11.13M |
| Free cash flow | n/a | n/a | -$8.56M | -$11.13M |
| Cash & equivalents | $11.85M | $13.16M | n/a | $7.56M |
| Total assets | $13.97M | $14.04M | $14.04M | $13.81M |
| Total liabilities | $123.69M | $6.11M | $10.12M | $1.48M |
| Shareholders' equity | -$109.72M | $7.92M | $3.93M | $12.33M |
| Return on year-end equity | n/a | -280.5% | -126.0% | -72.9% |
| Shares outstanding | 1.37B | 23.25M | 6.37M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | CytoDyn Inc. | Actuate Therapeutics, Inc. | Exicure, Inc. | Chemomab Therapeutics Ltd. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-05-31 | n/a | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | $266.0K Ended 2022-05-31 | n/a | $500.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $0 Ended 2021-05-31 | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $28.83M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | -$483.0K Ended 2021-12-31 | n/a |